Dilated cardiomyopathy

  • Carl V. Leier
Article
  • 60 Downloads

Opinion statement

The management of patients with dilated cardiomyopathy (DCM) heart failure starts with the determination of the underlying diagnosis, definition of the hemodynamic character (eg, systolic, diastolic, valvular, right- and left-sided heart dysfunction), recognition of complicating factors (eg, atrial fibrillation, renal dysfunction), and consideration for any surgically remedial lesions (eg, severe valvular regurgitation, high-grade coronary artery occlusive disease). Angiotensin-converting enzyme inhibitors, beta-blocking agents, digoxin, and judicious diuretic administration make up the therapeutic plan for patients with symptomatic DCM heart failure. Angiotensin-converting enzymes are indicated for patients with DCM who have mild or no detectable symptoms; whether this subgroup would benefit from long-term betablockade remains to be established. Spirolactone also has been shown to be effective in patients with more advanced stages of heart failure. Biventricular pacing (cardiac resynchronization therapy) recently has been approved for use in patients with DCM and a left ventricular or intraventricular conduction defect and a QRS duration of longer than 140 msec. More intense pharmacotherapy, mechanical devices, and transplantation are directed at patients with severely symptomatic end-stage DCM. The effectiveness of any heart failure treatment plan is very much dependent on nonpharmacologic approaches, including dietary measures, exercise conditioning, and similar considerations, all of which are best delivered by dedicated heart failure programs.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Guidelines for the evaluation and management of heart Failure. Report of the American College of Cardiology/ American Heart Association task force on practice guidelines (Committee on Evaluation and Management of Heart Failure). Circulation 1995, 92:2754–2784.Google Scholar
  2. 2.
    Packer M, Cohn JN, Abraham WT, et al.: Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999, 83:1A-99A.CrossRefGoogle Scholar
  3. 3.
    Heart Failure Society of America (HFSA). Practice guidelines committee. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction—pharmacologic choices. J Cardiac Fail 1999, 5:357–382. An excellent update on the current management of patients with chronic heart failure, well referenced and reader friendly, by a panel of heart failure experts.CrossRefGoogle Scholar
  4. 4.
    Sullivan MJ, Higginbotham MB, Cobb FR: Exercise training in patients with chronic heart failure delays ventilatory anaerobic threshold and improves submaximal exercise performance. Circulation 1989, 79:324–329. This is a report of an early, nicely performed, pivotal study looking at the clinical and physiologic effects of exercise training in patients with heart failure.PubMedGoogle Scholar
  5. 5.
    Coats AHS, Adamopoulus S, Radaelli A, et al.: Controlled trial of physical training in chronic heart failure: exercise performance, hemodynamics, ventilation and autonomic function. Circulation 1992, 85:2119–2131.PubMedGoogle Scholar
  6. 6.
    The CONCENSUS Trial study group: Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987, 316:1429–1435. This trial demonstrated the survival benefit of the use of enalapril in patients with severe heart failure.CrossRefGoogle Scholar
  7. 7.
    The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293–302. The benefits of long-term enalapril in patients with NYHA functional class II to III heart failure were established in this trial.CrossRefGoogle Scholar
  8. 8.
    The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327:685–691. This study demonstrated that patients with left ventricular systolic dysfunction and mild to no symptoms benefit from long-term ACE inhibitor therapy.CrossRefGoogle Scholar
  9. 9.
    Packer M, Bristow MR, Cohn JN, et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996, 334:1349–1355. This report presents aggregate data from several carvedilol trials performed in this country.PubMedCrossRefGoogle Scholar
  10. 10.
    MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999, 353:2001–2007. This report presents the results of the trial establishing a role for extended release metoprolol succinate as a beta-blocker choice in heart failure.CrossRefGoogle Scholar
  11. 11.
    CIBIS Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomized trial of beta blockade in heart failure. Lancet 1999, 353:9–13.CrossRefGoogle Scholar
  12. 12.
    Packer M, Coats AJ, Fowler MB, et al.: Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe heart failure. N Engl J Med 2001, 344:1651–1658. This study supports the use of beta-blockade in the more advanced stages of heart failure.PubMedCrossRefGoogle Scholar
  13. 13.
    Leier CV, Dei Cas L, Metra M: Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. Am Heart J 1994, 128:564–574.PubMedCrossRefGoogle Scholar
  14. 14.
    Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709–717. This is report of the RALES (Randomized Aldactone Evaluation Study) trial demonstrating survival benefit from long-term spironolactone in patients with NYHA functional class IV or those recently hospitalized with functional class III heart failure.PubMedCrossRefGoogle Scholar
  15. 15.
    The Digitalis Investigation Group (DIG). The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997, 336:525–533. This large multinational, multicenter controlled trial demonstrated a beneficial effect of long-term digoxin therapy in chronic heart failure. Net survival was not altered by digoxin.CrossRefGoogle Scholar
  16. 16.
    DiBianco R, Shabetai R, Kostak W, et al.: A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989, 320:677–683.PubMedCrossRefGoogle Scholar
  17. 17.
    Gheorghiade M, Hall VB, Jacobsen G, et al.: Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients which chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors. Circulation 1995, 92:1801–1807.PubMedGoogle Scholar
  18. 18.
    Nicolozakes AW, Binkley PF, Leier CV: Hemodynamic effects of smoking in congestive heart failure. Am J Med Sci 1988, 296:377–380.PubMedCrossRefGoogle Scholar
  19. 19.
    Evangelista LS, Doering LV, Dracup K: Usefulness of a history of tobacco and alcohol use in predicting multiple heart failure readmissions among veterans. Am J Cardiol 2000, 86:1339–1342.PubMedCrossRefGoogle Scholar
  20. 20.
    Cozier I, Ikram H, Awan N, et al.: Losartan in heart failure: hemodynamic effects and tolerability. Circulation 1995, 91:691–697.Google Scholar
  21. 21.
    Cohn JN, Archbald DG, Ziesche S, et al.: Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration cooperative study (V-HeFT). N Engl J Med 1986, 324:1547–1552. This pivotal study was the first to demonstrate that any therapy could favorably impact the high mortality of heart failure; vasodilators were tested in this study.CrossRefGoogle Scholar
  22. 22.
    Cohn JN, Johnson G, Ziesche S, et al.: A comparison of enalapril with hydralazine dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991, 325:303–310.PubMedCrossRefGoogle Scholar
  23. 23.
    Binkley PF, Starling RC, Hammer DF, Leier CV: Usefulness of hydralazine to withdraw from dobutamine in severe congestive heart failure. Am J Cardiol 1991, 69:1103–1106.CrossRefGoogle Scholar
  24. 24.
    Leier CV, Huss P, Magorien RD, Unverferth DV: Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure. Circulation 1983, 67:817–822.PubMedGoogle Scholar
  25. 25.
    Gottlieb SS, Riggio DW, Lauria S, et al.: High dose oral amiodarone loading exerts important hemodynamic actions in patients with congestive heart failure. J Am Coll Cardiol 1993, 23:560–564.CrossRefGoogle Scholar
  26. 26.
    Doval HC, Nul DR, Grancelli HO, for the GESICA Investigators: Randomized trial of low dose amiodarone in severe congestive heart failure. Lancet 1994, 344:493–498.PubMedCrossRefGoogle Scholar
  27. 27.
    Singh SN, Fletcher RD, Fischer SG, for the CHF-STAT Investigators: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmias. N Engl J Med 1995, 333:77–82.PubMedCrossRefGoogle Scholar
  28. 28.
    Nul DR, Doval HC, Grancelli HO, et al., on behalf of the GESICA-GEMA Investigators: Heart rate is a marker of amiodarone mortality reduction in severe heart failure. J Am Coll Cardiol 1997, 29:1199–1205.PubMedCrossRefGoogle Scholar
  29. 29.
    Cazeau S, LeClercq C, Laverque T, et al.: Effects of multi-site ventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001, 344:373–380.CrossRefGoogle Scholar
  30. 30.
    Walker S, Levy TM, Coats AJS, et al.: Biventricular pacing in congestive heart failure. Eur Heart J 2000, 21:884–889.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2001

Authors and Affiliations

  • Carl V. Leier
    • 1
  1. 1.Division of Cardiology, Heart-Lung Research InstituteThe Ohio State University Medical CenterColumbusUSA

Personalised recommendations